BRAF、EGFR与MEK联合抑制治疗BRAFV600E突变结直肠癌
该临床试验在142例BRAFV600E结直肠癌患者中评估达拉非尼联合帕尼单抗,联合或不联合曲美替尼的疗效。D+P、D+T+P与T+P的确认缓解率分别为10%、21%与0%。药效学分析显示D+T+P的疗效与MAPK抑制增强相关,提示靶向适应性反馈通路可提高疗效,但MAPK再激活仍是原发与获得性耐药的重要机制。
要点
- BRAFV600E结直肠癌对BRAF单药抑制的应答率仅约5%。
- D+T+P的确认缓解率为21%,高于D+P的10%与T+P的0%。
- D+T+P的疗效与MAPK抑制增强相关,MAPK再激活是耐药重要机制。
核心结论
- 联合抑制BRAF、EGFR与MEK在BRAFV600E结直肠癌中可耐受,并显示出有前景的抗肿瘤活性。
- MAPK通路是BRAFV600E结直肠癌的关键治疗靶点,但MAPK再激活仍是原发与获得性耐药的重要机制。
研究设计与样本
- 该临床试验在142例BRAFV600E结直肠癌患者中评估达拉非尼联合帕尼单抗,联合或不联合曲美替尼的疗效。
- 研究分析了配对治疗前与治疗中活检的药效学,并进行了连续游离DNA分析。
主要发现
- D+P、D+T+P与T+P的确认缓解率分别为10%、21%与0%。
- 配对活检药效学分析发现D+T+P的疗效与MAPK抑制增强相关。
- 连续游离DNA分析揭示了额外的应答相关因素,以及疾病进展时出现的KRAS和NRAS突变。
临床怎么用
- 对于BRAFV600E结直肠癌,可考虑BRAF+EGFR+MEK联合抑制策略,但需关注MAPK再激活导致的原发与获得性耐药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although BRAF inhibitor monotherapy yields response rates >50% in BRAFV600-mutant melanoma, only approximately 5% of patients with BRAFV600E colorectal cancer respond. Preclinical studies suggest that the lack of efficacy in BRAFV600E colorectal cancer is due to adaptive feedback reactivation of MAPK signaling, often mediated by EGFR. This clinical trial evaluated BRAF and EGFR inhibition with dabrafenib (D) + panitumumab (P) ± MEK inhibition with trametinib (T) to achieve greater MAPK suppression and improved efficacy in 142 patients with BRAFV600E colorectal cancer. Confirmed response rates for D+P, D+T+P, and T+P were 10%, 21%, and 0%, respectively. Pharmacodynamic analysis of paired pretreatment and on-treatment biopsies found that efficacy of D+T+P correlated with increased MAPK suppression. Serial cell-free DNA analysis revealed additional correlates of response and emergence of KRAS and NRAS mutations on disease progression. Thus, targeting adaptive feedback pathways in BRAFV600E colorectal cancer can improve efficacy, but MAPK reactivation remains an important primary and acquired resistance mechanism.Significance: This trial demonstrates that combined BRAF + EGFR + MEK inhibition is tolerable, with promising activity in patients with BRAFV600E colorectal cancer. Our findings highlight the MAPK pathway as a critical target in BRAFV600E colorectal cancer and the need to optimize strategies inhibiting this pathway to overcome both primary and acquired resistance. Cancer Discov; 8(4); 428-43. ©2018 AACR.See related commentary by Janku, p. 389See related article by Hazar-Rethinam et al., p. 417This article is highlighted in the In This Issue feature, p. 371.
引用
- Corcoran RB, André T, Atreya CE, et al. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer. Cancer Discov. 2018. PMID: 29431699. doi:10.1158/2159-8290.CD-17-1226
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。